News & Analysis on Clinical Trial Services & Contract Research And Development
A potential vaccine for the deadly ricin, a "Category B" biological agent, is to proceed with the first phase of human clinical testing of RiVax, a genetically engineered vaccine for the toxin for which there is currently no effective vaccine or...
A naturally occurring protein, which promotes the ability to repair heart muscle after a myocardial infarction, significantly reducing cardiac damage, may have drug applications as a wound healing treatment for the heart.
The need for a new class of antibiotics to tackle the rising threat of antibiotic resistance was the focus of a drug discovery agreement between two UK companies. The deal aims to produce broad-spectrum antibiotics that are urgently needed to treat...
A new anti-infectives company, spun out of the Sanofi-Aventis group, has received €40 million in financing from an international group of leading life science investors led by Atlas Venture and including Sofinnova, 3i, Abingworth and Novo A/S.
A technique used to conduct fully automated high throughput mutation detection in microbial genomes, has shown greater sensitivity over existing methods. The method analyses genetic modification in bacteria and other disease causing organisms,...
WellSpring Pharmaceuticals has been awarded a US patent for the synthetic method of preperation for a new drug being developed for the treatment of jaundice in newborns.
New laws to stop increasingly violent animal extremists from harassing scientists involved in medical experiments have received the seal of approval by the Association of the British Pharmaceutical Industry (ABPI).
Invitrogen announced that it has obtained the licensed rights for the development of protein microrrays, which contain more than 200 protein-based analytes, further increasing its intellectual property position in the burgeoning microarray field.